Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ordem dos Médicos
2018-08-01
|
| Series: | Acta Médica Portuguesa |
| Subjects: | |
| Online Access: | https://actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 |
| _version_ | 1818195302992052224 |
|---|---|
| author | Guilherme Ferreira-Dos-Santos David Cordeiro Sousa João Costa António Vaz-Carneiro |
| author_facet | Guilherme Ferreira-Dos-Santos David Cordeiro Sousa João Costa António Vaz-Carneiro |
| author_sort | Guilherme Ferreira-Dos-Santos |
| collection | DOAJ |
| description | Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice. |
| first_indexed | 2024-12-12T01:16:02Z |
| format | Article |
| id | doaj.art-dc97e7de277d42d5a877264a7c5c2b78 |
| institution | Directory Open Access Journal |
| issn | 0870-399X 1646-0758 |
| language | English |
| last_indexed | 2024-12-12T01:16:02Z |
| publishDate | 2018-08-01 |
| publisher | Ordem dos Médicos |
| record_format | Article |
| series | Acta Médica Portuguesa |
| spelling | doaj.art-dc97e7de277d42d5a877264a7c5c2b782022-12-22T00:43:21ZengOrdem dos MédicosActa Médica Portuguesa0870-399X1646-07582018-08-01317-837638110.20344/amp.104334751Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002Guilherme Ferreira-Dos-Santos0David Cordeiro Sousa1João Costa2António Vaz-Carneiro3Departamento de Medicina Física e Reabilitação. Hospital de Curry Cabral. Centro Hospitalar de Lisboa Central. Lisboa. Centro de Estudos de Medicina Baseada na Evidência (CEMBE-HEALTH). Faculdade de Medicina. Universidade de Lisboa. Lisboa. Centro Colaborador Português da Rede Iberoamericana. Cochrane Portugal. Faculdade de Medicina. Universidade de Lisboa. Lisboa.Serviço de Oftalmologia. Hospital de Santa Maria. Centro Hospitalar de Lisboa Norte. Lisboa. Centro de Estudos das Ciências da Visão. Faculdade de Medicina. Universidade de Lisboa. Lisboa.Centro de Estudos de Medicina Baseada na Evidência (CEMBE-HEALTH). Faculdade de Medicina. Universidade de Lisboa. Lisboa. Centro Colaborador Português da Rede Iberoamericana. Cochrane Portugal. Faculdade de Medicina. Universidade de Lisboa. Lisboa.Centro de Estudos de Medicina Baseada na Evidência (CEMBE-HEALTH). Faculdade de Medicina. Universidade de Lisboa. Lisboa. Centro Colaborador Português da Rede Iberoamericana. Cochrane Portugal. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Instituto de Medicina Preventiva. Faculdade de Medicina. Universidade de Lisboa. Lisboa.Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.https://actamedicaportuguesa.com/revista/index.php/amp/article/view/10433Dor CrónicaEnsaios Clínicos AleatorizadosFibromialgiaPregabalinaRevisão Sistemática |
| spellingShingle | Guilherme Ferreira-Dos-Santos David Cordeiro Sousa João Costa António Vaz-Carneiro Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 Acta Médica Portuguesa Dor Crónica Ensaios Clínicos Aleatorizados Fibromialgia Pregabalina Revisão Sistemática |
| title | Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
| title_full | Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
| title_fullStr | Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
| title_full_unstemmed | Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
| title_short | Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002 |
| title_sort | analysis of the cochrane review pregabalin for pain in fibromyalgia in adults cochrane database syst rev 2016 9 cd011790 and 2016 4 cd009002 |
| topic | Dor Crónica Ensaios Clínicos Aleatorizados Fibromialgia Pregabalina Revisão Sistemática |
| url | https://actamedicaportuguesa.com/revista/index.php/amp/article/view/10433 |
| work_keys_str_mv | AT guilhermeferreiradossantos analysisofthecochranereviewpregabalinforpaininfibromyalgiainadultscochranedatabasesystrev20169cd011790and20164cd009002 AT davidcordeirosousa analysisofthecochranereviewpregabalinforpaininfibromyalgiainadultscochranedatabasesystrev20169cd011790and20164cd009002 AT joaocosta analysisofthecochranereviewpregabalinforpaininfibromyalgiainadultscochranedatabasesystrev20169cd011790and20164cd009002 AT antoniovazcarneiro analysisofthecochranereviewpregabalinforpaininfibromyalgiainadultscochranedatabasesystrev20169cd011790and20164cd009002 |